Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Lack of BRAFV600E mutation in stage I and II of colorectal cancer.

Molaei M, Kishani Farahani R, Maftouh M, Taleghani MY, Vahdatinia M, Khatami F, Nazemalhosseini-Mojarad E, Asadzadeh Aghdae H, Aboutorabi A, Zali MR.

Gastroenterol Hepatol Bed Bench. 2016 Spring;9(2):94-9.

2.

Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.

Murcia O, Juárez M, Hernández-Illán E, Egoavil C, Giner-Calabuig M, Rodríguez-Soler M, Jover R.

World J Gastroenterol. 2016 Apr 7;22(13):3516-30. doi: 10.3748/wjg.v22.i13.3516. Review.

3.

BRAF gene: From human cancers to developmental syndromes.

Hussain MR, Baig M, Mohamoud HS, Ulhaq Z, Hoessli DC, Khogeer GS, Al-Sayed RR, Al-Aama JY.

Saudi J Biol Sci. 2015 Jul;22(4):359-73. doi: 10.1016/j.sjbs.2014.10.002. Epub 2014 Oct 23. Review.

4.

Methionine adenosyltransferase 2B-GIT1 complex serves as a scaffold to regulate Ras/Raf/MEK1/2 activity in human liver and colon cancer cells.

Peng H, Li TW, Yang H, Moyer MP, Mato JM, Lu SC.

Am J Pathol. 2015 Apr;185(4):1135-44. doi: 10.1016/j.ajpath.2014.12.016.

5.

Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.

Korphaisarn K, Pongpaibul A, Limwongse C, Roothumnong E, Klaisuban W, Nimmannit A, Jinawath A, Akewanlop C.

World J Gastroenterol. 2015 Jan 21;21(3):926-34. doi: 10.3748/wjg.v21.i3.926.

6.

Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.

Lemieux E, Cagnol S, Beaudry K, Carrier J, Rivard N.

Oncogene. 2015 Sep 17;34(38):4914-27. doi: 10.1038/onc.2014.416. Epub 2014 Dec 15.

7.
8.

hMLH1 promoter methylation and BRAF mutations in high-frequency microsatellite instability colorectal cancers not fulfilling the revised Bethesda guidelines.

Kim SJ, Kim HR, Kim SH, Han JH, Cho YB, Yun SH, Lee WY, Kim HC.

Ann Surg Treat Res. 2014 Sep;87(3):123-30. doi: 10.4174/astr.2014.87.3.123. Epub 2014 Aug 26.

9.

Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks.

Zhao H, Thienpont B, Yesilyurt BT, Moisse M, Reumers J, Coenegrachts L, Sagaert X, Schrauwen S, Smeets D, Matthijs G, Aerts S, Cools J, Metcalf A, Spurdle A; ANECS, Amant F, Lambrechts D.

Elife. 2014 Aug 1;3:e02725. doi: 10.7554/eLife.02725.

10.

A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.

Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T, Gibbs P, Sieber O, Waring P, Desai J.

Target Oncol. 2015 Mar;10(1):99-109. doi: 10.1007/s11523-014-0319-8. Epub 2014 May 27.

11.

Molecular profile of colorectal cancer in Indonesia: is there another pathway?

Abdullah M, Sudoyo AW, Utomo AR, Fauzi A, Rani AA.

Gastroenterol Hepatol Bed Bench. 2012 Spring;5(2):71-8. Review.

12.

Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.

Kim JH, Kang GH.

World J Gastroenterol. 2014 Apr 21;20(15):4230-43. doi: 10.3748/wjg.v20.i15.4230. Review.

13.

Translating clinical research of Molecular Biology into a personalized, multidisciplinary approach of colorectal cancer patients.

Strambu V, Garofil D, Pop F, Radu P, Bratucu M, Popa F.

J Med Life. 2014 Mar 15;7(1):17-26. Epub 2014 Mar 25.

14.

Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.

Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, DeWire M, Smith PD, Kurmasheva RT, Mo X, Fernandez S, Houghton PJ.

Clin Cancer Res. 2013 Dec 15;19(24):6716-29. doi: 10.1158/1078-0432.CCR-13-0842. Epub 2013 Oct 16.

15.

Markers of resistance to anti-EGFR therapy in colorectal cancer.

Shaib W, Mahajan R, El-Rayes B.

J Gastrointest Oncol. 2013 Sep;4(3):308-18. doi: 10.3978/j.issn.2078-6891.2013.029.

16.

Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer.

Bruegl AS, Djordjevic B, Urbauer DL, Westin SN, Soliman PT, Lu KH, Luthra R, Broaddus RR.

Curr Pharm Des. 2014;20(11):1655-63.

17.

Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JD, Vnencak-Jones CL.

Clin Colorectal Cancer. 2013 Sep;12(3):168-78. doi: 10.1016/j.clcc.2013.04.005. Epub 2013 Jun 14.

18.

Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.

Mouliere F, El Messaoudi S, Gongora C, Guedj AS, Robert B, Del Rio M, Molina F, Lamy PJ, Lopez-Crapez E, Mathonnet M, Ychou M, Pezet D, Thierry AR.

Transl Oncol. 2013 Jun 1;6(3):319-28. Print 2013 Jun.

19.

MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features.

Li X, Yao X, Wang Y, Hu F, Wang F, Jiang L, Liu Y, Wang D, Sun G, Zhao Y.

PLoS One. 2013;8(3):e59064. doi: 10.1371/journal.pone.0059064. Epub 2013 Mar 29. Review.

20.

Right-sided rhabdoid colorectal tumors might be related to the serrated pathway.

Pancione M, Remo A, Sabatino L, Zanella C, Votino C, Fucci A, Di Blasi A, Lepore G, Daniele B, Fenizia F, Molinari E, Normanno N, Manfrin E, Vendraminelli R, Colantuoni V.

Diagn Pathol. 2013 Feb 20;8:31. doi: 10.1186/1746-1596-8-31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk